Th17 and Th17/Treg ratio at early HIV infection associate with protective HIV-specific CD8+ T-cell responses and disease progression

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Falivene, Juliana ^a   Ghiglione, Yanina ^a   Laufer, Natalia ^a,c   Socías, María Eugenia ^b   Holgado, María Pía ^a   Ruiz, María Julia ^a   Maeto, Cynthia ^a   Figueroa, María Inés ^b   Giavedoni, Luis D ^d   Cahn, Pedro ^b,c   Salomón, Horacio ^a   Sued, Omar ^b   Turk, Gabriela ^a   Gherardi, María Magdalena ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b FUNDACIÓN HUÉSPED   (Argentina)

^c HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^d SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CD8+ T LYMPHOCYTE; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; REGULATORY T LYMPHOCYTE; TH17 CELL; VIRUS LOAD;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; VIRAL LOAD;

EID: 84932607502     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11511     Document Type: Article

References (49)

1. Park, H. et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6, 1133-1141 (2005).
2. Harrington, L. E. et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6, 1123-1132 (2005).
3. Blaschitz, C. & Raffatellu, M. Th17 cytokines and the gut mucosal barrier. J Clin Immunol 30, 196-203 (2010).
4. Cook, D. N. et al. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity 12, 495-503 (2000).
5. Kolls, J. K. & Linden, A. Interleukin-17 family members and inflammation. Immunity 21, 467-476 (2004).
6. Onishi, R. M. & Gaffen, S. L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129, 311-321 (2010).
7. Brenchley, J. M. et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112, 2826-2835 (2008).
8. Prendergast, A. et al. HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS (London, England) 24, 491-502 (2010).
9. Kanwar, B., Favre, D. & McCune, J. M. Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr Opin HIV AIDS 5, 151-157 (2010).
10. Bixler, S. L. & Mattapallil, J. J. Loss and dysregulation of Th17 cells during HIV infection. Clin Dev Immunol 2013, 852418 (2013).
11. Turk, G. et al. Early Gag immunodominance of the HIV-specific T-cell response during acute/early infection is associated with higher CD8+ T-cell antiviral activity and correlates with preservation of the CD4+ T-cell compartment. Journal of virology 87, 7445-7462 (2013).
12. Fiebig, E. W. et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (London, England) 17, 1871-1879 (2003).
13. Chevalier, M. F. et al. The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS pathogens 9, e1003453 (2013).
14. Favre, D. et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2, 32ra36 (2010).
15. Cocchi, F. et al. Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of beta chemokines and RNases. Proceedings of the National Academy of Sciences of the United States of America 109, 5411-5416 (2012).
16. Jenabian, M. A. et al. Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T-cell expansion in HIV infection. Clin Exp Immunol 178, 102-111 (2014).
17. Yang, H. et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. The Journal of infectious diseases 206, 552-561 (2012).
18. Favre, D. et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS pathogens 5, e1000295 (2009).
19. Krishnan, S. et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis 209, 931-939 (2014).
20. Pereyra, F. et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS (London, England) 26, 2409-2412 (2012).
21. Hunt, P. W. et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 197, 126-133 (2008).
22. Brandt, L. et al. Low level of regulatory T cells and maintenance of balance between regulatory T cells and TH17 cells in HIV- 1-infected elite controllers. J Acquir Immune Defic Syndr 57, 101-108 (2011).
23. Singh, A., Vajpayee, M., Ali, S. A. & Chauhan, N. K. Cellular interplay among Th17, Th1, and Treg cells in HIV-1 subtype "C" infection. J Med Virol 86, 372-384 (2014).
24. Li, D. et al. Loss of balance between T helper type 17 and regulatory T cells in chronic human immunodeficiency virus infection. Clin Exp Immunol 165, 363-371 (2011).
25. Socias, M. E. et al. Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. J Int AIDS Soc 14, 40 (2011).
26. Olson, A. D. et al. Evaluation of rapid progressors in HIV infection as an extreme phenotype. Journal of acquired immune deficiency syndromes (1999) 67, 15-21 (2014).
27. Lambert, J. S. et al. Production of the HIV-suppressive chemokines CCL3/MIP-1alpha and CCL22/MDC is associated with more effective antiretroviral therapy in HIV-infected children. Pediatr Infect Dis J 26, 935-944 (2007).
28. Geiben-Lynn, R. et al. Noncytolytic inhibition of X4 virus by bulk CD8(+) cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by beta-chemokines. Journal of virology 75, 8306-8316 (2001).
29. Moriuchi, H. & Moriuchi, M. Dichotomous effects of macrophage-derived chemokine on HIV infection. AIDS (London, England) 13, 994-996 (1999).
30. Cota, M. et al. Selective inhibition of HIV replication in primary macrophages but not T lymphocytes by macrophage-derived chemokine. Proceedings of the National Academy of Sciences of the United States of America 97, 9162-9167 (2000).
31. Macal, M. et al. Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal immunology 1, 475-488 (2008).
32. Hartigan-O'Connor, D. J., Abel, K., Van Rompay, K. K., Kanwar, B. & McCune, J. M. SIV replication in the infected rhesus macaque is limited by the size of the preexisting TH17 cell compartment. Sci Transl Med 4, 136ra169 (2012).
33. Chevalier, M. F. et al. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. Journal of virology 85, 733-741 (2011).
34. Wherry, E. J. & Ahmed, R. Memory CD8 T-cell differentiation during viral infection. Journal of virology 78, 5535-5545 (2004).
35. Fuller, M. J. & Zajac, A. J. Ablation of CD8 and CD4 T cell responses by high viral loads. J Immunol 170, 477-486 (2003).
36. Kostense, S. et al. High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur J Immunol 31, 677-686 (2001).
37. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188, 2205-2213 (1998).
38. Wei, L., Laurence, A., Elias, K. M. & O'Shea, J. J. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 282, 34605-34610 (2007).
39. Barker, B. R., Gladstone, M. N., Gillard, G. O., Panas, M. W. & Letvin, N. L. Critical role for IL-21 in both primary and memory anti-viral CD8+ T-cell responses. European journal of immunology 40, 3085-3096 (2010).
40. Novy, P., Huang, X., Leonard, W. J. & Yang, Y. Intrinsic IL-21 signaling is critical for CD8 T cell survival and memory formation in response to vaccinia viral infection. J Immunol 186, 2729-2738 (2011).
41. Yi, J. S., Ingram, J. T. & Zajac, A. J. IL-21 deficiency influences CD8 T cell quality and recall responses following an acute viral infection. J Immunol 185, 4835-4845 (2010).
42. Nurieva, R. et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448, 480-483 (2007).
43. Korn, T. et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448, 484-487 (2007).
44. Pallikkuth, S. et al. Maintenance of intestinal Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with interleukin (IL)-21. PLoS pathogens 9, e1003471 (2013).
45. Kim, C. J. et al. Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol 191, 2164-2173 (2013).
46. He, Y. et al. A randomized case-control study of dynamic changes in peripheral blood Th17/Treg cell balance and interleukin-17 levels in highly active antiretroviral-treated HIV type 1/AIDS patients. AIDS research and human retroviruses 28, 339-345 (2012).
47. Schuetz, A. et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS pathogens 10, e1004543 (2014).
48. Ghiglione, Y. et al. Early Skewed Distribution of Total and HIV-Specific CD8+ T-Cell Memory Phenotypes during Primary HIV Infection Is Related to Reduced Antiviral Activity and Faster Disease Progression. PLoS One 9, e104235 (2014).
49. Giavedoni, L. D. Simultaneous detection of multiple cytokines and chemokines from nonhuman primates using luminex technology. J Immunol Methods 301, 89-101 (2005).